Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms
Debra Van Egeren(Boston Children's Hospital), Sahand Hormoz(Broad Institute), Ann Mullally(Brigham and Women's Hospital), Fernando D. Camargo(Boston Children's Hospital), Maximilian Nguyen(Harvard University), Marlise R. Luskin(Harvard University), Maria Kalyva(European Bioinformatics Institute), Baransel Kamaz(Brigham and Women's Hospital), Martha Wadleigh(Dana-Farber Cancer Institute), Ilene Galinsky(Dana-Farber Cancer Institute), Javier Escabi(Harvard University), Christopher R. Reilly(Dana-Farber Cancer Institute), Gabriela Hobbs(Massachusetts General Hospital), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Isidro Cortés‐Ciriano(Harvard University), Franziska Michor(Harvard University), Sachin Patel(Boston Children's Hospital), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Shichen Liu(Dana-Farber Cancer Institute), Eric S. Winer(Providence College)
Cited by 209
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k